The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies
Abstract
We performed an individual patient meta-analysis to determine whether aspirin has a significant protective effect on the risk of first thrombosis among patients with antiphospholipid antibodies (aPL). Five international cohort studies with available individual patient-level data, reporting on primary prophylaxis with continuous treatment with low-dose aspirin in patients with aPL were included. The main outcome was the occurrence of a first thrombotic in patients with aPL treated with low-dose aspirin compared to those not treated with low-dose aspirin. Pooled Hazard Ratios (HRs) and 95%CIs were calculated using frailty models. We pooled data from 497 subjects and 79 first thrombotic events (3469 patient-years of follow-up). After adjustment on cardiovascular risk factors, aPL profiles, and treatment with hydroxychloroquine, the HR for the risk of a first thrombosis of any type in aPL carriers treated with low-dose aspirin versus those not treated with aspirin was 0.43 (95%CI 0.25-0.75). Subgroup analysis showed a protective effect of aspirin against arterial (HR: 0.43 [95%CI: 0.20-0.93]) but not venous (HR: 0.49 [95%CI: 0.22-1.11]) thrombosis. Subgroup analysis according to underlying disease revealed a protective effect of aspirin against arterial thrombosis for systemic lupus erythematosus (SLE) (HR: 0.43 [95%CI: 0.20-0.94]) and asymptomatic aPL carriers (HR: 0.43 [95%CI 0.20-0.93]). We found no independent protective effect of hydroxychloroquine. This individual patient data meta-analysis shows that the risk of first thrombotic event as well of first arterial thrombotic event is significantly decreased among SLE patients and asymptomatic aPL individuals treated by low-dose aspirin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an individual patient analysis, this association was independent of the use of hydroxychloroquine (HCQ), suggesting that LDA offers additional benefit in this patient group.15”
From EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) · cites this paper as [15]
In the citing paper
“An association of similar magnitude was present in a smaller individual patient meta-analysis derived from these studies.15”
From EULAR recommendations for the management of antiphospholipid syndrome in adults (2019) · cites this paper as [15]
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E., Buonaiuto, V, Jacobsen, S., Zeher, M. M., Tarr, T., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204838 · Cited by 974
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340232 · Cited by 468 · cited 1×
“Wepooled data from 2 prospective [11,13] and 3 retrospective [12,13, 17] cohort studies.”
BackgroundUrbanus, R. T., Siegerink, B., Roest, M., Rosendaal, F. R., de Groot, P. G., & Algra, A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70239-x · Cited by 429
Erkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Cited by
Sorted by citations
EULAR recommendations for the management of antiphospholipid syndrome in adults
Tektonidou, M. G., Andreoli, L., Limper, M., Amoura, Z., Cervera, R., Costedoat-Chalumeau, N., Cuadrado, M. J., Dörner, T., Ferrer-Oliveras, R., Hambly, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215213 · Cited by 1,318
Al‐Bari, M. A. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv018 · Cited by 477
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O. C., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 443
de Abreu, M. M., Danowski, A., Wahl, D. G., Amigo, M., Tektonidou, M. G., Pacheco, M. D. S., Fleming, N. R. P., Domingues, V., Sciascia, S., Lyra, J. O., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.002 · Cited by 227
The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus
Ünlü, O., Zuily, S., & Erkan, D. (2015) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2015.0085 · Cited by 212
New therapeutic strategies in systemic lupus erythematosus management
Gatto, M., Zen, M., Iaccarino, L., & Doria, A. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0133-2 · Cited by 186
Corban, M., Duarte‐García, A., McBane, R. D., Matteson, E. L., Lerman, L. O., & Lerman, A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.058 · Cited by 186
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 170
Liu, D., Li, X., Zhang, Y., Kwong, J. S. W., Li, L., Zhang, Y., Xu, C., Li, Q., Sun, X., Tian, H., et al. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166893 · Cited by 116
Groot, N., de Graeff, N., Avčin, T., Bader‐Meunier, B., Doležalová, P., Feldman, B. M., Kenet, G., Koné‐Paut, I., Lahdenne, P., Marks, S. D., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-211001 · Cited by 115
Management of antiphospholipid syndrome
Uthman, I. W., Noureldine, M. H. A., Ruiz‐Irastorza, G., & Khamashta, M. A. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213846 · Cited by 114
Current treatment of antiphospholipid syndrome: lights and shadows
Espinosa, G., & Cervera, R. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.88 · Cited by 110
Fasano, S., Pierro, L., Pantano, I., Iudici, M., & Valentini, G. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.161351 · Cited by 111
Petri, M. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.006 · Cited by 113
Tektonidou, M. G., Andréoli, L., Limper, M., Tincani, A., & Ward, M. M. (2019) · RMD Open · doi:10.1136/rmdopen-2019-000924 · Cited by 101
Pastori, D., Menichelli, D., Cammisotto, V., & Pignatelli, P. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.715878 · Cited by 109
Antiphospholipid syndrome – an update
Linnemann, B. (2018) · VASA · doi:10.1024/0301-1526/a000723 · Cited by 86
Pediatric Antiphospholipid Syndrome
Cimaz, R., & Descloux, É. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.05.005 · Cited by 81
Yelnik, C. M., Urbanski, G., Drumez, E., Sobanski, V, Maillard, H., Lanteri, A., Morell-Dubois, S., Caron, C., Dubucquoi, S., Launay, D., et al. (2017) · Lupus · doi:10.1177/0961203316657433 · Cited by 73
Self-citationThe treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 66
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach
Ambati, A., Knight, J. S., & Zuo, Y. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000932 · Cited by 68
Obstetric antiphospholipid syndrome
Antovič, A., Sennström, M., Bremme, K. A., & Svenungsson, E. (2018) · Lupus Science & Medicine · doi:10.1136/lupus-2016-000197 · Cited by 67
Pregnancy-related complications in systemic lupus erythematosus
Tan, Y., Yang, S., Liu, Q., Li, Z., Mu, R., Qiao, J., & Cui, L. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102864 · Cited by 67
Justiz-Vaillant, A. A., Gopaul, D. A., Soodeen, S., Arozarena-Fundora, R., Arozarena-Barbosa, O., Unakal, C., Thompson, R., Pandit, B., Umakanthan, S., & Akpaka, P. E. (2024) · Molecules · doi:10.3390/molecules29040747 · Cited by 62
Recent advances in the diagnosis and management of neuropsychiatric lupus
Legge, A. C., & Hanly, J. G. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01163-z · Cited by 66
Pediatric antiphospholipid syndrome
Madison, J. A., Zuo, Y., & Knight, J. S. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2019.19160 · Cited by 55
Bała, M. M., Paszek, E., Leśniak, W., Włoch-Kopeć, D., Jasińska, K., & Undas, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012534.pub2 · Cited by 47
Membranous Lupus Nephritis: A Clinical Review
Almaani, S. J., & Parikh, S. V. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.009 · Cited by 47
Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies
Tortosa, C., Cabrera-Marante, O., Serrano, M., Martínez-Flores, J. A., Pérez, D., Lora, D., Morillas, L., Paz-Artal, E., Morales, J. M., Pleguezuelo, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178889 · Cited by 44
Iudici, M., Fasano, S., Falcone, L. G., Pantano, I., MONTAGNA, G. L., Migliaresi, S., & Valentini, G. (2016) · Rheumatology · doi:10.1093/rheumatology/kew231 · Cited by 46
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 44
VWF, Platelets and the Antiphospholipid Syndrome
Huang, S., Ninivaggi, M., Chayouâ, W., & de Laat, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084200 · Cited by 40
Update on the pathogenesis and treatment of the antiphospholipid syndrome
Chighizola, C. B., Raschi, E., Borghi, M. O., & Meroni, P. L. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000200 · Cited by 40
The antiphospholipid syndrome – often overlooked cause of vascular occlusions?
Svenungsson, E., & Antovič, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13022 · Cited by 39
Pediatric Antiphospholipid Syndrome
Aguiar, C. L., Soybilgic, A., Avčin, T., & Myones, B. L. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0504-5 · Cited by 39
Antiphospholipid Antibodies in Lupus Nephritis
Parodis, I., Arnaud, L., Gerhardsson, J., Zickert, A., Sundelin, B., Malmström, V., Svenungsson, E., & Gunnarsson, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158076 · Cited by 37
Platelets and Thrombotic Antiphospholipid Syndrome
Tohidi‐Esfahani, I., Mittal, P., Isenberg, D. A., Cohen, H., & Efthymiou, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030741 · Cited by 40
Pediatric APS: State of the Art
Soybilgic, A., & Avčin, T. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-0887-9 · Cited by 37
Wang, T., & Lim, W. (2016) · Hematology · doi:10.1182/asheducation-2016.1.714 · Cited by 30
Positive antiphospholipid antibodies: observation or treatment?
Grygiel‐Górniak, B., & Mazurkiewicz, Ł. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02834-6 · Cited by 32
Management of Antiphospholipid Syndrome
Ghembaza, A., & Saadoun, D. (2020) · Biomedicines · doi:10.3390/biomedicines8110508 · Cited by 50
Aspirin and multiple sclerosis
Tsau, S., Emerson, M. R., LYNCH, S. G., & LeVine, S. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0394-4 · Cited by 31
Diagnosis and treatment of antiphospholipid syndrome in childhood: A review
Rumsey, D. G., Myones, B. L., & Massicotte, P. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.02.009 · Cited by 30
Schlencker, A., Messer, L., Ardizzone, M., Blaison, G., Hinschberger, O., Dahan, É., Sordet, C., Walther, J., Dory, A., Gonzalez, M., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000700 · Cited by 30
Simonin, L., Pasquier, É., Leroyer, C., Cornec, D., Lemerle, J., Bendaoud, B., Hillion, S., Pers, J., Couturaud, F., & Renaudineau, Y. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8568-1 · Cited by 29
Under crossfire: thromboembolic risk in systemic lupus erythematosus
Ramirez, G. A., Efthymiou, M., Isenberg, D. A., & Cohen, H. (2018) · Rheumatology · doi:10.1093/rheumatology/key307 · Cited by 29
Recognition and management of antiphospholipid syndrome
Gerosa, M., Meroni, P. L., & Erkan, D. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000240 · Cited by 26
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 26
Management of cardiovascular disease in patients with systemic lupus erythematosus
Piranavan, P., & Perl, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1770227 · Cited by 26
Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management
Rosina, S., Chighizola, C. B., Ravelli, A., & Cimaz, R. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-020-00976-7 · Cited by 26
Prevention of thrombosis in antiphospholipid syndrome
Lim, W. (2016) · Hematology · doi:10.1182/asheducation-2016.1.707 · Cited by 25
Zuo, Y., Barbhaiya, M., & Erkan, D. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0775-8 · Cited by 25
Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects
Islabão, A. G., da Trindade, V. C., da Mota, L. M. H., ANDRADE, D. C. O. D., & Silva, C. A. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00484-w · Cited by 24
Management of cardiovascular risk in systemic lupus erythematosus: a systematic review
Andrades, C., Fuego, C., Arija, S. M., & Fernández‐Nebro, A. (2017) · Lupus · doi:10.1177/0961203317704710 · Cited by 23
Preclinical and early systemic lupus erythematosus
Gatto, M., Saccon, F., Zen, M., Iaccarino, L., & Doria, A. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.06.004 · Cited by 20
Cesbron, E., Bessis, D., Jachiet, M., Lipsker, D. M., Cordel, N., Bouaziz, J., Bagot, M., Arnaud, L., Barbaud, A. M., Francès, C., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.02.049 · Cited by 20
Ruiz‐Irastorza, G., Tektonidou, M. G., & Khamashta, M. A. (2024) · Rheumatology · doi:10.1093/rheumatology/kead538 · Cited by 22
Gauthier, M., Canouï‐Poitrine, F., Guéry, E., Desvaux, D., Hüe, S., Canaud, G., Stehlé, T., Lang, P., Kofman, T., Grimbert, P., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx353 · Cited by 20
Nigolian, H., Ribi, C., Courvoisier, D. S., Pagano, S., Alvarez, M., Trendelenburg, M., Huynh‐Do, U., Vuilleumier, N., Dayer, J., Chizzolini, C., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez306 · Cited by 19
Sciascia, S., Radin, M., Cecchi, I., Levy, R. A., & Erkan, D. (2021) · Lupus · doi:10.1177/09612033211020361 · Cited by 19
What is known about pediatric antiphospholipid syndrome?
Meroni, P. L., Argolini, L. M., & Pontikaki, I. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1235969 · Cited by 18
Moulinet, T., Dufrost, V., Clerc‐Urmès, I., Wahl, D. G., & Zuily, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.10.011 · Cited by 19
Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus
Yuan, W.-J., & Guan, F. (2022) · Autoimmune Diseases · doi:10.1155/2022/3208037 · Cited by 20
Hisada, R., & Atsumi, T. (2023) · Biomolecules · doi:10.3390/biom13040617 · Cited by 18
Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's
Arnaud, L., Conti, F., Massaro, L., Denas, G., Chasset, F., & Pengo, V. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.09.003 · Cited by 16
Management of antiphospholipid syndrome
Rahman, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05183-4 · Cited by 18
Antiphospholipid Syndrome: State of the Art of Clinical Management
Depietri, L., Veropalumbo, M. R., Leone, M. C., & Ghirarduzzi, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07496-3 · Cited by 16
Bernardi, M., Spadafora, L., Andaloro, S., Piscitelli, A., Fornaci, G., Intonti, C., Fratta, A. E., Hsu, C.-E., Kaziród-Wolski, K., Metsovitis, T., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113064 · Cited by 16
Prevention of Pregnancy Complications in Antiphospholipid Syndrome
Czwalinna, A., & Bergmann, F. (2020) · Hämostaseologie · doi:10.1055/a-1113-0689 · Cited by 14
Pregnancy Management in Women with Antiphospholidic Syndrome
Radu, A., Dudu, S. C., Ciobanu, A. M., Peltecu, G. C., Iancu, G., Botezatu, R., Gică, N., & Panaitescu, A. M. (2019) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2019.14.2.148 · Cited by 15
Legault, K., Ugarte, A., Crowther, M. A., & Ruiz‐Irastorza, G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0573-0 · Cited by 14
Wu, T., Huang, W., Qi, J., Li, Y., Zhang, Y., Jiang, H., Wang, J., Zhang, J., Jiang, Z.-Y., Chen, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1035229 · Cited by 13
Prevention and Treatment of Thrombotic Antiphospholipid Syndrome
Crowther, M. A., Legault, K., Garcia, D. A., Tektonidou, M. G., Ugarte, A., Bruce, I. N., Erkan, D., & Ruiz‐Irastorza, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_11 · Cited by 12
Clinical profiles and risk assessment in patients with antiphospholipid antibodies
Kato, M., Hisada, R., & Atsumi, T. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1543025 · Cited by 13
Antiphospholipid syndrome in pediatric patients
Tarango, C., & Palumbo, J. S. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000523 · Cited by 12
French National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children
Amoura, Z., Bader‐Meunier, B., Sollier, C. B. D., Bélot, A., Benhamou, Y., Bézanahary, H., Aubart, F. C., Costedoat-Chalumeau, N., Darnige, L., Drouet, L. O., et al. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.08.004 · Cited by 13
Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?
Calcaterra, I. L., Tufano, A., Lupoli, R., Iannuzzo, G., Emmi, G., & Minno, M. N. D. D. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15415 · Cited by 12
Treatment in thrombotic antiphospholipid syndrome: a review
Vadgama, T. S., Smith, A., & Bertolaccini, M. L. (2019) · Lupus · doi:10.1177/0961203319864163 · Cited by 10
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Ortells, L. C., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.004 · Cited by 10
Antiphospholipid syndrome in children
Avramovič, M. Z., & Avčin, T. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101986 · Cited by 11
Selmi, C. F. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8576-1 · Cited by 9
Risk factors of first thrombosis in obstetric antiphospholipid syndrome
Luo, L., Cai, Q., Liu, X., Hou, Y., & Li, C. (2024) · Lupus Science & Medicine · doi:10.1136/lupus-2023-001044 · Cited by 9
A importância de reconhecer a síndrome antifosfolípide na medicina vascular
Funke, A., Danowski, A., ANDRADE, D. C. O. D., Rêgo, J., & Levy, R. A. (2017) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.011416 · Cited by 14
Antiphospholipid antibodies and cardiovascular thrombosis
Rashedi, S., Leyva, H., Siddiqui, S. A., Bukhari, S., Pfeferman, M. B., Watson, N. W., Ujueta, F., Zarghami, M., Bacare, B., Kanthi, Y. M., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01269-9 · Cited by 10
Tang, C., Wang, Y., Lei, D., Huang, L., Wang, G., Chi, Q., Zheng, Y., Gachet, C., Mangin, P., & Zhu, L. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.02.032 · Cited by 8
Just, S. A., Nybo, M., Laustrup, H., Hansen, I. M. J., Junker, P., & Vinholt, P. J. (2015) · Lupus · doi:10.1177/0961203315604040 · Cited by 8
Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus
Quintana, R., Pons‐Estel, G., Serrano, R., Pons‐Estel, B. A., & Bruce, I. N. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.03.002 · Cited by 8
Semczuk-Kaczmarek, K., Platek, A. E., Ryś-Czaporowska, A., Szymański, F. M., & Filipiak, K. J. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100552 · Cited by 8
Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers
Calcaterra, I. L., Ambrosino, P., Vitelli, N., Lupoli, R., Orsini, R. C., Chiurazzi, M., Maniscalco, M., & Minno, M. N. D. D. (2021) · Biomedicines · doi:10.3390/biomedicines9020122 · Cited by 9
Ugarte, A., & Ruiz‐Irastorza, G. (2016) · Lupus · doi:10.1177/0961203316652948 · Cited by 8
Cardiovascular Outcomes in Systemic Lupus Erythematosus
Sairam, S., Sureen, A., Gutierrez, J., Dang, T. Q., & Mishra, K. (2022) · Current Cardiology Reports · doi:10.1007/s11886-021-01626-9 · Cited by 7
The Antiphospholipid Syndrome in the Pediatric Population
Sloan, E. E., & McCurdy, D. (2022) · Advances in Pediatrics · doi:10.1016/j.yapd.2022.03.013 · Cited by 5
Alfehaid, L., Alsuhebany, N., Albahlal, H. N., Alomran, A., Alshehri, A. M., Alsheef, M. A., & Almutairi, A. R. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251364269 · Cited by 5
Controversies in the Management of Antiphospholipid Syndrome
Porta, S., ANDRADE, D. C. O. D., Erkan, D., Gómez-Puerta, J. A., Jara, L. J., Moreyra, P. A., & Pons‐Estel, G. (2023) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001961 · Cited by 5
Antiphospholipid syndrome in cardiovascular disease and cancer
Pessach, I., Kyriakou, E. S., Kalampokas, E., Kalampokas, T., Bitsani, A., & Kotsianidis, Ι. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14096 · Cited by 8
Barilaro, G., Espinosa, G., & Cervera, R. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.03.012 · Cited by 7
Pediatric antiphospholipid syndrome: is it the same as an adult?
Bitsadze, V., Khizroeva, J. K., Владимировна, Л. А., Владимировна, С. П., Yagubova, F. E., Tretyakova, M. V., Grigoreva, K. N., Gashimova, N. R., Tsibizova, V. I., Карпова, А. Л., et al. (2024) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2024.2390637 · Cited by 7
Thrombotic antiphospholipid syndrome: From guidelines to clinical management
Paredes, D., Martín‐Iglesias, D., & Ruiz‐Irastorza, G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.02.010 · Cited by 6
Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE
Luggen, M. E., Gulati, G., Zhang, B., Willis, R., & González, E. B. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-3114-8 · Cited by 4
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Ortells, L. C., et al. (2019) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.11.013 · Cited by 4
Metadata
- Authors
- Arnaud, L., Mathian, A., Devilliers, H., Ruffatti, A., Tektonidou, M., Forastiero, R., Pengo, V., Lambert, M., Lefevre, G., Martinez-Zamora, M. A., Balasch, J., Wahl, D., & Amoura, Z.
- Affiliations
- Inserm (FR)
- Sorbonne Université (FR)
- University of Padua (IT)
- National and Kapodistrian University of Athens (GR)
- Favaloro University (AR)
- Centre Hospitalier Universitaire de Lille (FR)
- Hospital Clínic de Barcelona (ES)
- Corresponding author
- Arnaud, Laurent
- ORCID
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 14
- Issue
- 3
- Pages
- 192-200
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2052413901
- Cited by
- 146
- References
- 30
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 20 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 17 · 2018: 14 · 2017: 13 · 2016: 12 · 2015: 13
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Autoimmunity Reviews (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- aspirin, antiphospholipid antibodies, low-dose aspirin, arterial thrombosis, venous thrombosis, systemic lupus erythematosus, hydroxychloroquine, individual patient data meta-analysis, thrombosis risk
- MeSH terms
- Aspirin, Humans, Primary Prevention, Risk Factors, Thrombosis, Cohort Studies, Treatment Outcome, Antibodies, Antiphospholipid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
